Europe Veterinary Active Pharmaceutical Ingredients (APIs) Market is segmented By Product Type (Antiparasitics, Anti-infectives, NSAIDs & Anesthetics, Others), By Animal Type (Companion Animals, Livestock Animals), By Route of Administration (Oral, Intravenous, Others), By End-User (Animal Healthcare Products Manufacturers, Academic and Research Organizations, Others), and By Region (Germany, U.K, France, Italy, Spain, Rest of Europe) – Share, Size, Outlook, and Opportunity Analysis, 2024-2031
Report Overview
The Europe veterinary active pharmaceutical ingredients (APIs) market reached US$ 2 Billion in 2023 and is expected to reach US$ 3.42 million by 2031, growing at a CAGR of 7.1% during the forecast period 2024-2031.
Veterinary active pharmaceutical ingredients are relative to finished preparations and are the main components of finished preparations. Most APIs are a class of substances obtained by chemical synthesis, biotechnology synthesis, or extraction of natural drugs by raw material manufacturers. Veterinary APIs are the upstream chemicals in the manufacture of finished drugs, and the quality of veterinary finished medicines directly depends on the quality of the API.
The starting material should have clear chemical properties and chemical structure. Mixtures and unpurified compounds generally cannot start materials should be incorporated into the structure of the API as important structural fragments. Still, at the same time, it should be avoided that the starting material already includes the main structure of the API. The starting material should be a structural fragment of the API and should not be structurally too close to the API as the starting material.
Market Scope
|
Metrics |
Details |
|
CAGR |
7.1% |
|
Market Size |
2022-2031 |
|
Market Estimation Forecast Period |
2024-2031 |
|
Revenue Units |
Value (US$ Mn) |
|
Segments Covered |
Product Type, Animal Type, Route of Administration, and End-User |
|
Report Insights Covered |
Competitive Landscape Analysis, Company Profile Analysis, Market Size, Share, Growth, Demand, Recent Developments, Mergers and Acquisitions, New Product Launches, Growth Strategies, Revenue Analysis, Porter's Analysis, Pricing Analysis, Regulatory Analysis, Supply-Chain Analysis, and Other key Insights. |
For more details on this report - Request for Sample
Market Dynamics: Drivers
Increasing prevalence of transboundary and zoonotic diseases
The demand for the Europe veterinary active pharmaceutical ingredients market is driven by multiple factors. The rising prevalence of transboundary and zoonotic diseases propels the market growth.
Furthermore, the demand for treatment will be fueled by technological advancements, as well as government initiatives and funds. For instance, according to an article published by Istituto Zooprofilattico Sperimentale delle Venezie (IZSVe), campylobacteriosis and salmonellosis were the most frequently reported zoonotic diseases in humans in the EU in 2022. For West Nile virus, an increase in the number of infections was observed. There was a general increase (+44%) in cases of zoonotic outbreaks and foodborne illnesses, from 4,005 in 2021 to 5,763 outbreaks in 2022, reaching similar levels as during the pre-pandemic years.
Campylobacteriosis is the single most frequently reported zoonotic disease, with 137,107 cases. Chicken (broiler) and turkey meat was the most common source of the infections. Salmonellosis was the second most reported zoonotic disease (65,208), followed by yersiniosis (7,917), STEC infections (7,117), and listeriosis (2,738). In 2022 it was observed the highest number of outbreak-related deaths in the past decade (64). Deaths were primarily attributed to Listeria monocytogenes and were associated with a wide variety of foods, ranging from meat and dairy products to fish and vegetables.
In 2022, 431 birds and 166 horses tested positive for West Nile virus in the EU, around double the previous year’s figures. The virus also extended its geographical area, reaching previously unaffected areas (southwestern France, northern Germany, and southern Italy).
Restraints
Factors such as high cost associated with the treatment, and stringent regulatory requirements for the approval of new treatments are expected to hamper the market.
Market Segment Analysis
The Europe veterinary active pharmaceutical ingredients market is segmented based on product type, animal type, route of administration, and end-user.
The segment anti-parasitics accounted for approximately 44.3% of the Europe veterinary active pharmaceutical ingredients market share
The anti-parasitics segment is expected to hold the largest market share over the forecast period. In this segment, the development of government regulation, and rising funds for private manufacturers for research work would drive this market.
Antiparasitics (AP) are substances that kill or interrupt the development of parasites. Within the European Union (EU), APs fall under the definition of VMPs. VMPs are substances or combinations of substances that treat or prevent a disease or that restore, correct or modify physiological functions. Antiparasitics are used to treat or prevent an infection, infestation, or disease caused or transmitted by parasites, including substances with a repelling activity.
For instance, according to an article published by MDPI in January 2022, biological VMPs belong either to the new class, non-immunological VMPs, or immunologicals, including those known as vaccines. This new regulation also defines novel therapies covering innovative medicinal therapeutic approaches. Antiparasitic products will always be VMPs, and additional requirements for environmental safety and potential risks for the development of resistance are enforced.
Market Segmentation
By Product Type
- Anti-parasitics
- Anti-infectives
- NSAIDs & Anesthetics
- Others
- Gastroenteric
- Cardiovascular
- Beta Agonists
By Animal Type
- Companion Animals
- Livestock Animals
By Route of Administration
- Oral
- Intravenous
- Others
By End-User
- Animal Health Product Manufacturers
- Academic and Research Organizations
- Others
Market Competitive Landscape
The major global players in the Europe veterinary active pharmaceutical ingredients (APIs) market include Glenmark Pharmaceuticals Ltd., Zoetis Services Ltd., Eli Lilly and Company, Sanofi, Indukern Group, Ofichem Group, Olon, Lonza Group, Huve Pharma, and Sequent Scientific among others.
Key Developments
- In April 2024, Lonza, a global partner in the pharmaceutical, biotech, and nutraceutical sectors, announced the introduction of its AI-enabled Route Scouting Service (RSS). This offering aims to streamline the identification of synthetic routes for novel active pharmaceutical ingredients (APIs) by using Lonza's extensive chemical supply chain intelligence and in-house expertise, combined with AI technology from Elsevier (Reaxys).
Why Purchase the Report?
- To visualize the Europe veterinary active pharmaceutical ingredients market segmentation based on product type, animal type, route of administration, and end-user, as well as understand key commercial assets and players.
- Identify commercial opportunities by analyzing trends and co-development
- Excel data sheet with numerous data points of Europe veterinary active pharmaceutical ingredients market level with all segments.
- PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
- Product mapping is available in Excel consisting of key products of all the major players.
The Europe veterinary active pharmaceutical ingredients market report would provide approximately 51 tables, 54 figures, and 181 Pages.
Target Audience 2024
- Manufacturers/ Buyers
- Industry Investors/Investment Bankers
- Research Professionals
- Emerging Companies
